Last reviewed · How we verify
fenofibrate/omega
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and improve lipid profiles, while omega-3 fatty acids provide additional triglyceride-lowering and anti-inflammatory effects.
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and improve lipid profiles, while omega-3 fatty acids provide additional triglyceride-lowering and anti-inflammatory effects. Used for Hypertriglyceridemia, Dyslipidemia with elevated triglycerides.
At a glance
| Generic name | fenofibrate/omega |
|---|---|
| Sponsor | Gachon University Gil Medical Center |
| Drug class | Fibrate + omega-3 fatty acid combination |
| Target | PPARα (peroxisome proliferator-activated receptor alpha) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fenofibrate is a fibrate that works primarily through PPARα activation, which increases lipolysis and reduces VLDL production, thereby lowering triglycerides and raising HDL cholesterol. The addition of omega-3 fatty acids (likely eicosapentaenoic acid and/or docosahexaenoic acid) provides complementary triglyceride reduction and anti-inflammatory benefits. This combination targets dyslipidemia and cardiovascular risk reduction through complementary mechanisms.
Approved indications
- Hypertriglyceridemia
- Dyslipidemia with elevated triglycerides
Common side effects
- Myalgia
- Elevated liver enzymes
- Gastrointestinal upset
- Headache
Key clinical trials
- Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients (PHASE4)
- Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fenofibrate/omega CI brief — competitive landscape report
- fenofibrate/omega updates RSS · CI watch RSS
- Gachon University Gil Medical Center portfolio CI